LitAlert ~~ GeneLit.com

    • BRCA-2 (+) high-grade serous fallopian tube cancer diagnosed as an isolated breast mass by mammography.
    • Sobecki JN, Dryer KA, Mahajan AM, Spencer RJ.
    • Gynecol Oncol Rep. 2020 Dec 25;35:100690. doi: 10.1016/j.gore.2020.100690. eCollection 2021 Feb.
    • Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
    • Kim DS, Camacho CV, Kraus WL.
    • Exp Mol Med. 2021 Jan 25. doi: 10.1038/s12276-021-00557-3. Epub ahead of print.
    • A pathogenic germline BRCA2 variant in a patient with hypopharyngeal squamous cell carcinoma.
    • Correa T, Laux DE, Hoffman HT.
    • Clin Case Rep. 2020 Nov 25;9(1):429-432. doi: 10.1002/ccr3.3548. eCollection 2021 Jan.
    • Alterations of DNA damage repair in cancer: from mechanisms to applications.
    • Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, Wang H, Zhao S, He Y, Zhou C.
    • Ann Transl Med. 2020 Dec;8(24):1685. doi: 10.21037/atm-20-2920.
    • Current practices on genetic testing in ovarian cancer.
    • Fostira F, Papadimitriou M, Papadimitriou C.
    • Ann Transl Med. 2020 Dec;8(24):1703. doi: 10.21037/atm-20-1422.
    • Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
    • Boussios S, Moschetta M, Karihtala P, Samartzis EP, Sheriff M, Pappas-Gogos G, Ozturk MA, Uccello M, Karathanasi A, Tringos M, Rassy E, Pavlidis N.
    • Ann Transl Med. 2020 Dec;8(24):1706. doi: 10.21037/atm.2020.03.156.